Candidates / 7774

Japan Tissue Engineering Co., Ltd.7774・Precision instruments

TEIJIN LIMITED owns 58% (controlling). Of the listed companies with this trait in 2021–22, 1 in 4 was bought in the following four years or so — against 1 in 11 for all listed companies.

Taking every trait together, its score is 4.0x the average — #25 of 3,751. The closest type of deal is strategic buyer.

Score4.0xvs average; #25 of 3,751
Past, similar score1 in 4were bought (24%)
Closest typeStrategic
Price-to-book6.65xmarket value ¥33.9bn

Why it looks like past targets

Score by type of buyer

Typevs average for the type
Buyout by the parent4.6x
Management buyout0.6x
Private equity4.0x
Strategic buyer4.6x

Ownership

Top 10 shareholders

HolderTypeStake
帝人株式会社Company57.7%
株式会社ニデックCompany10.4%
前田 陽子Individual0.8%
五味 大輔Individual0.8%
小澤 洋介Individual0.7%
J-TEC従業員持株会Employee/partner plan0.6%
サーラエナジー株式会社Company0.4%
上田八木短資株式会社Company0.4%
楽天証券株式会社Custodian/nominee0.3%
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC)Custodian/nominee0.3%

From the annual report for the year to 2026-03-31. Holder types are assigned by name and can be wrong (for example, a founder’s company can look like an operating company). Annual report (PDF, EDINET)

Key figures

Controlling shareholder (over 50%)
Yes
Largest corporate holder
57.7%
Founder family (individuals and their companies)
2.4%
Officers
0.3%
Net cash ÷ market value
—
ROE
—
Equity ratio
90%

This site ranks listed companies by how closely their public filings (annual reports and large-shareholding reports) resemble past tender-offer and MBO targets. It is not a prediction that any company will be bought, is not based on any non-public information, and is not a recommendation to buy or sell. Not investment advice.

Updated 29 Sep 2026 00:48 JST